Tolterodine/pilocarpine

Drug Profile

Tolterodine/pilocarpine

Alternative Names: THVD-201; THVD-202

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator TheraVida
  • Developer SK Chemicals; TheraVida
  • Class Alkaloids; Antispasmodics; Benzhydryl compounds; Cresols
  • Mechanism of Action Muscarinic receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Overactive bladder

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Overactive bladder in USA (PO)
  • 10 Aug 2015 No recent reports on development identified - Phase-II for Overactive bladder in Australia, New Zealand (PO)
  • 02 Apr 2013 Tolterodine/pilocarpine licensed to SK Chemicals in South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top